{"id":20597,"date":"2023-10-17T16:16:20","date_gmt":"2023-10-17T14:16:20","guid":{"rendered":"https:\/\/ggba.swiss\/lonza-expands-to-manufacture-vaxcytes-pneumococcal-conjugate-vaccine\/"},"modified":"2023-10-17T16:20:15","modified_gmt":"2023-10-17T14:20:15","slug":"lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/","title":{"rendered":"Lonza s&rsquo;agrandit pour fabriquer le vaccin pneumococcique conjugu\u00e9 de Vaxcyte"},"content":{"rendered":"\n<p>Dans le cadre de l&rsquo;accord r\u00e9cemment sign\u00e9, <a href=\"https:\/\/www.lonza.com\/\">Lonza<\/a> fournira \u00e0 Vaxcyte une unit\u00e9 de production sur mesure au sein du Ibex Dedicate Biopark sur son site de Vi\u00e8ge. Cette unit\u00e9 permettra de produire des composants essentiels, y compris des substances m\u00e9dicamenteuses, pour les projets PCV de Vaxcyte. La conception de la ligne est presque achev\u00e9e et l&rsquo;installation de l&rsquo;\u00e9quipement devrait commencer en 2024. L&rsquo;expansion de l&rsquo;installation devrait g\u00e9n\u00e9rer jusqu&rsquo;\u00e0 300 nouvelles opportunit\u00e9s d&#8217;emploi lorsqu&rsquo;elle atteindra sa capacit\u00e9 maximale.<\/p>\n\n\n\n<p><a href=\"https:\/\/vaxcyte.com\/\">Vaxcyte<\/a> se concentre sur la conception de vaccins de haute fid\u00e9lit\u00e9 pour prot\u00e9ger les humains des r\u00e9percussions des maladies bact\u00e9riennes. Son principal candidat, VAX-24, vise \u00e0 pr\u00e9venir les maladies pneumococciques invasives. Son approche innovante de la production de vaccins complexes, comprenant une chimie avanc\u00e9e et la plateforme de synth\u00e8se de prot\u00e9ines acellulaires XpressCF, vise \u00e0 acc\u00e9l\u00e9rer la cr\u00e9ation et l&rsquo;administration de vaccins puissants.<\/p>\n\n\n\n<p>Grant Pickering, CEO et cofondateur de Vaxcyte, a soulign\u00e9 l&rsquo;importance de ce partenariat : \u00ab&nbsp;Apr\u00e8s la r\u00e9ussite de nos \u00e9tudes de phase 2 sur le VAX-24 chez l&rsquo;adulte, nous sommes ravis de renforcer notre partenariat avec Lonza.&nbsp;\u00bb Il a exprim\u00e9 sa confiance dans la nouvelle unit\u00e9 de production d\u00e9di\u00e9e, estimant qu&rsquo;elle permettra de r\u00e9pondre efficacement aux demandes potentielles d&rsquo;approvisionnement en VAX-24 et, par la suite, en VAX-31, \u00e0 l&rsquo;\u00e9chelle mondiale.<\/p>\n\n\n\n<p>Les progr\u00e8s de Vaxcyte au cours de l&rsquo;ann\u00e9e \u00e9coul\u00e9e ont \u00e9t\u00e9 notables, en particulier dans le cadre de son programme clinique VAX-24. Les r\u00e9sultats positifs de deux \u00e9tudes de phase 2 chez les adultes et le lancement d&rsquo;une \u00e9tude de phase 2 chez les nourrissons renforcent sa position.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Renforcement d&rsquo;un partenariat de longue date<\/h4>\n\n\n\n<p>\u00ab&nbsp;Notre relation \u00e9largie avec Vaxcyte souligne la valeur de nos services dans le cadre du processus de commercialisation&nbsp;\u00bb, a d\u00e9clar\u00e9 Jean-Christophe Hyvert, pr\u00e9sident de la division Biologics de Lonza. \u00ab&nbsp;Apr\u00e8s avoir soutenu le d\u00e9veloppement clinique pr\u00e9coce des programmes PCV de Vaxcyte, nous sommes heureux de poursuivre notre collaboration de longue date en soutenant la fabrication clinique en phase avanc\u00e9e gr\u00e2ce \u00e0 notre offre unique Ibex Dedicate.&nbsp;\u00bb<\/p>\n\n\n\n<p>Fond\u00e9e en 1897 dans les Alpes suisses, Lonza est aujourd&rsquo;hui un leader mondial dans les secteurs de la pharmacie, de la biotechnologie et de la nutrition. Avec environ 17&rsquo;500 employ\u00e9s, Lonza a pour objectif de contribuer \u00e0 un monde en meilleure sant\u00e9 en aidant ses clients \u00e0 mettre au point des m\u00e9dicaments innovants pour une myriade de maladies. L&rsquo;entreprise a d\u00e9clar\u00e9 un chiffre d&rsquo;affaires de CHF 3,1 milliards avec un CORE EBITDA de CHF 922 millions au cours du premier semestre 2023.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lonza et la soci\u00e9t\u00e9 am\u00e9ricaine Vaxcyte, sp\u00e9cialis\u00e9e dans l&rsquo;innovation vaccinale de stade clinique, ont annonc\u00e9 le renforcement de leur partenariat afin de mettre en place une capacit\u00e9 de production commerciale mondiale pour les candidats vaccins conjugu\u00e9s antipneumococciques (PCV) de Vaxcyte.<\/p>\n","protected":false},"author":6,"featured_media":20593,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1155,1169,1171,1143],"class_list":["post-20597","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-advanced-manufacturing-fr-2","tag-biotech-fr-2","tag-pharma-fr-2","tag-vaccines-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lonza va fabriquer le vaccin pneumococcique conjugu\u00e9 de Vaxcyte<\/title>\n<meta name=\"description\" content=\"Lonza et Vaxcyte se sont associ\u00e9s pour fabriquer le vaccin antipneumococciques conjugu\u00e9 (PCV) candidat de Vaxcyte.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lonza va fabriquer le vaccin pneumococcique conjugu\u00e9 de Vaxcyte\" \/>\n<meta property=\"og:description\" content=\"Lonza et Vaxcyte se sont associ\u00e9s pour fabriquer le vaccin antipneumococciques conjugu\u00e9 (PCV) candidat de Vaxcyte.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-17T14:16:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-17T14:20:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/IPD-Lonza-Pneumococcal-2360x1622-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2360\" \/>\n\t<meta property=\"og:image:height\" content=\"1622\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Lonza s&rsquo;agrandit pour fabriquer le vaccin pneumococcique conjugu\u00e9 de Vaxcyte\",\"datePublished\":\"2023-10-17T14:16:20+00:00\",\"dateModified\":\"2023-10-17T14:20:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/\"},\"wordCount\":469,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/IPD-Lonza-Pneumococcal-2360x1622-1.jpeg\",\"keywords\":[\"Advanced Manufacturing\",\"Biotech\",\"Pharma\",\"Vaccines\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/\",\"name\":\"Lonza va fabriquer le vaccin pneumococcique conjugu\u00e9 de Vaxcyte\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/IPD-Lonza-Pneumococcal-2360x1622-1.jpeg\",\"datePublished\":\"2023-10-17T14:16:20+00:00\",\"dateModified\":\"2023-10-17T14:20:15+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Lonza et Vaxcyte se sont associ\u00e9s pour fabriquer le vaccin antipneumococciques conjugu\u00e9 (PCV) candidat de Vaxcyte.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/IPD-Lonza-Pneumococcal-2360x1622-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/IPD-Lonza-Pneumococcal-2360x1622-1.jpeg\",\"width\":2360,\"height\":1622,\"caption\":\"Cette derni\u00e8re collaboration vient compl\u00e9ter la strat\u00e9gie de Vaxcyte visant \u00e0 entamer le premier lancement commercial du VAX-24, un vaccin destin\u00e9 \u00e0 la pr\u00e9vention des maladies pneumococciques invasives (\\\" invasive pneumococcal disease \\\" ou IPD).\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lonza s&#8217;agrandit pour fabriquer le vaccin pneumococcique conjugu\u00e9 de Vaxcyte\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lonza va fabriquer le vaccin pneumococcique conjugu\u00e9 de Vaxcyte","description":"Lonza et Vaxcyte se sont associ\u00e9s pour fabriquer le vaccin antipneumococciques conjugu\u00e9 (PCV) candidat de Vaxcyte.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/","og_locale":"fr_FR","og_type":"article","og_title":"Lonza va fabriquer le vaccin pneumococcique conjugu\u00e9 de Vaxcyte","og_description":"Lonza et Vaxcyte se sont associ\u00e9s pour fabriquer le vaccin antipneumococciques conjugu\u00e9 (PCV) candidat de Vaxcyte.","og_url":"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2023-10-17T14:16:20+00:00","article_modified_time":"2023-10-17T14:20:15+00:00","og_image":[{"width":2360,"height":1622,"url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/IPD-Lonza-Pneumococcal-2360x1622-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Lonza s&rsquo;agrandit pour fabriquer le vaccin pneumococcique conjugu\u00e9 de Vaxcyte","datePublished":"2023-10-17T14:16:20+00:00","dateModified":"2023-10-17T14:20:15+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/"},"wordCount":469,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/IPD-Lonza-Pneumococcal-2360x1622-1.jpeg","keywords":["Advanced Manufacturing","Biotech","Pharma","Vaccines"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/","url":"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/","name":"Lonza va fabriquer le vaccin pneumococcique conjugu\u00e9 de Vaxcyte","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/IPD-Lonza-Pneumococcal-2360x1622-1.jpeg","datePublished":"2023-10-17T14:16:20+00:00","dateModified":"2023-10-17T14:20:15+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Lonza et Vaxcyte se sont associ\u00e9s pour fabriquer le vaccin antipneumococciques conjugu\u00e9 (PCV) candidat de Vaxcyte.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/IPD-Lonza-Pneumococcal-2360x1622-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/IPD-Lonza-Pneumococcal-2360x1622-1.jpeg","width":2360,"height":1622,"caption":"Cette derni\u00e8re collaboration vient compl\u00e9ter la strat\u00e9gie de Vaxcyte visant \u00e0 entamer le premier lancement commercial du VAX-24, un vaccin destin\u00e9 \u00e0 la pr\u00e9vention des maladies pneumococciques invasives (\" invasive pneumococcal disease \" ou IPD)."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/lonza-sagrandit-pour-fabriquer-le-vaccin-pneumococcique-conjugue-de-vaxcyte\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Lonza s&#8217;agrandit pour fabriquer le vaccin pneumococcique conjugu\u00e9 de Vaxcyte"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/20597","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=20597"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/20597\/revisions"}],"predecessor-version":[{"id":20599,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/20597\/revisions\/20599"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/20593"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=20597"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=20597"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=20597"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}